Thomas Jemielita
Merck & Co., Inc., Rahway, NJ, USA (United States)
ORCID: 0000-0001-7788-1828Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas”.
Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan +7 more
Rachel Zhao, Tianrun Cai, Brett K. Beaulieu‐Jones, Thany Seyok, Kumar Dahal +10 more
Rachel Zhao, Jessica Gronsbell, Yucong Lin, Clara-Lea Bonzel, Qingyi Zeng +13 more